Current Diabetes Reports最新文献_第6页

Lessons and Applications of Omics Research in Diabetes Epidemiology. Omics 研究在糖尿病流行病学中的经验和应用。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1007/s11892-024-01533-7

Gechang Yu, Henry C H Tam, Chuiguo Huang, Mai Shi, Cadmon K P Lim, Juliana C N Chan, Ronald C W Ma

{"title":"Lessons and Applications of Omics Research in Diabetes Epidemiology.","authors":"Gechang Yu, Henry C H Tam, Chuiguo Huang, Mai Shi, Cadmon K P Lim, Juliana C N Chan, Ronald C W Ma","doi":"10.1007/s11892-024-01533-7","DOIUrl":"10.1007/s11892-024-01533-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent advances in genomic technology and molecular techniques have greatly facilitated the identification of disease biomarkers, advanced understanding of pathogenesis of different common diseases, and heralded the dawn of precision medicine. Much of these advances in the area of diabetes have been made possible through deep phenotyping of epidemiological cohorts, and analysis of the different omics data in relation to detailed clinical information. In this review, we aim to provide an overview on how omics research could be incorporated into the design of current and future epidemiological studies.</p><p><strong>Recent findings: </strong>We provide an up-to-date review of the current understanding in the area of genetic, epigenetic, proteomic and metabolomic markers for diabetes and related outcomes, including polygenic risk scores. We have drawn on key examples from the literature, as well as our own experience of conducting omics research using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank, as well as other cohorts, to illustrate the potential of omics research in diabetes. Recent studies highlight the opportunity, as well as potential benefit, to incorporate molecular profiling in the design and set-up of diabetes epidemiology studies, which can also advance understanding on the heterogeneity of diabetes. Learnings from these examples should facilitate other researchers to consider incorporating research on omics technologies into their work to advance the field and our understanding of diabetes and its related co-morbidities. Insights from these studies would be important for future development of precision medicine in diabetes.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"27-44"},"PeriodicalIF":4.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping Lifestyle Interventions for Gestational Diabetes Prevention: A Scoping Review 绘制预防妊娠糖尿病的生活方式干预图：范围审查

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2024-02-17 DOI: 10.1007/s11892-024-01535-5

Armando Peña, Alison M. Miller, Angela G. Campbell, Richard J. Holden, Christina M. Scifres

{"title":"Mapping Lifestyle Interventions for Gestational Diabetes Prevention: A Scoping Review","authors":"Armando Peña, Alison M. Miller, Angela G. Campbell, Richard J. Holden, Christina M. Scifres","doi":"10.1007/s11892-024-01535-5","DOIUrl":"https://doi.org/10.1007/s11892-024-01535-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>The purpose of this study was to conduct a scoping review to map intervention, sample, and physiologic measurement characteristics of lifestyle interventions for gestational diabetes mellitus (GDM) prevention.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>A total of 19 studies met selection criteria from 405 articles screened (PubMed, Web of Science). No studies were US-based (47% multi-site), and all were delivered in clinical settings. The most targeted nutrition components were low carbohydrate intake (sugar rich foods/added sugars, low glycemic index), low fat intake (mainly low-fat meat, dairy, and saturated fat), and increased fruits and vegetables. Many studies promoted 150 min/week moderate-intensity physical activity. Only two studies provided supervised physical activity sessions. Dietitians and nurses were the most common implementers. Samples were characterized as adults with obesity (mean age 31 yr, BMI 31 kg/m<sup>2</sup>). Asian populations were predominantly studied. Four studies used theoretical frameworks (75% of which used Social Cognitive Theory). GDM diagnostic criteria set forth by the American Diabetes Association were the most widely used. Insulin sensitivity was commonly assessed via fasting indices.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>There was a lack of multi-disciplinary, multi-level, and theory-based lifestyle interventions for reducing GDM risk. Addressing these gaps and prioritizing high-risk populations in the US with measurement of traditional and novel biomarkers will advance the field.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"70 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139759695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imeglimin: the New Kid on the Block. Imeglimin：街区的新生力量。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2024-01-01 Epub Date: 2023-12-05 DOI: 10.1007/s11892-023-01531-1

Sandeep Chandra Shrestha, Setu Gupta

{"title":"Imeglimin: the New Kid on the Block.","authors":"Sandeep Chandra Shrestha, Setu Gupta","doi":"10.1007/s11892-023-01531-1","DOIUrl":"10.1007/s11892-023-01531-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to collect all the data regarding imeglimin and present it as one of the options for managing diabetes.</p><p><strong>Recent findings: </strong>It is a new drug that has recently been approved as an oral anti-diabetic drug, either as monotherapy or in combination with other oral antidiabetic drugs including insulin, with modest HbA1c reduction, and a fairly safe profile. Imeglimin was first approved in 2021 in Japan and China and is available in India from October 2022. Imeglimin is the first compound in a new class of oral anti-diabetic medications known as \"glimins\" that include a tetrahydrotriazine ring. Glimins act by amplifying glucose-stimulated insulin secretion (GSIS) and preserving β-cell mass, leading to augmented insulin secretion. Furthermore, It also intensifies insulin action by inhibiting of hepatic glucose output and recovery of altered insulin signalling in both hepatocytes (liver) and myocytes (skeletal muscle). This is a unique mode of action than has been demonstrated to be distinct from other classes of drugs, as it targets both insulin secretion and insulin resistance by correcting the mitochondrial dysfunction. Imeglimin has been studied in various phase III trials which have equivocally shown it to be effective in lowering glucose levels and improving pancreatic function and its recommended dose set at 1000 mg bid.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"13-18"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138486946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polyagonists in Type 2 Diabetes Management. 2 型糖尿病管理中的多效肽。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2024-01-01 Epub Date: 2023-12-27 DOI: 10.1007/s11892-023-01530-2

H A Dissanayake, N P Somasundaram

{"title":"Polyagonists in Type 2 Diabetes Management.","authors":"H A Dissanayake, N P Somasundaram","doi":"10.1007/s11892-023-01530-2","DOIUrl":"10.1007/s11892-023-01530-2","url":null,"abstract":"<p><strong>Purpose of the review: </strong>This review summarizes the new developments in polyagonist pharmacotherapy for type 2 diabetes.</p><p><strong>Recent findings: </strong>Several dual- and triple-agonists targeting different pathogenic pathways of type 2 diabetes have entered clinical trials and have led to significant improvements in glycaemia, body weight, fatty liver, and cardio-renal risk factors, with variable adverse event profiles but no new serious safety concerns. Combining agents with complementary and synergistic mechanisms of action have enhanced efficacy and safety. Targeting multiple pathogenic pathways simultaneously has led to enhanced benefits which potentially match those of bariatric surgery. Tirzepatide, cotadutide, BI456906, ritatrutide, and CagriSema have entered phase 3 clinical trials. Outcomes from published clinical studies are reviewed. Efficacy-safety profiles are heterogeneous between agents, suggesting the potential application of precision medicine and need for personalized approach in pharmacological management of type 2 diabetes and obesity. Polyagonism has become a key strategy to address the complex pathogenesis of type 2 diabetes and co-morbidities and increasing number of agents are moving through clinical trials. Heterogeneity in efficacy-safety profiles calls for application of precision medicine and need for judicious personalization of care.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"1-12"},"PeriodicalIF":4.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Influencing Medication Adherence Among Adults Living with Diabetes and Comorbidities: a Qualitative Systematic Review 影响糖尿病患者和合并症患者坚持用药的因素：定性系统综述

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-12-19 DOI: 10.1007/s11892-023-01532-0

Kendall Gow, Amineh Rashidi, Lisa Whithead

{"title":"Factors Influencing Medication Adherence Among Adults Living with Diabetes and Comorbidities: a Qualitative Systematic Review","authors":"Kendall Gow, Amineh Rashidi, Lisa Whithead","doi":"10.1007/s11892-023-01532-0","DOIUrl":"https://doi.org/10.1007/s11892-023-01532-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>Medication adherence plays an important role in improving health outcomes related to diabetes and comorbidity. The potential factors influencing medication adherence and how they contribute to health behaviors have not been synthesized to date. This review synthesized qualitative studies that identified factors influencing medication adherence among adults living with diabetes and comorbidity.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Twenty-eight findings were extracted and synthesized into four themes: perceived support, lack of knowledge, medication issues, and the importance of routine. The findings highlight the factors that support medication adherence and areas that can be targeted to support and promote medication adherence. The findings also support the potential role of healthcare providers in supporting people living with diabetes and comorbidity to adhere to and maintain medication regimes.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Several factors were identified that are amenable to intervention within the clinical practice setting and have the potential to enhance medication adherence and improve health outcomes for people living with diabetes and comorbidities. The development of acceptable and effective interventions could have a positive effect on medication adherence and health outcomes.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"15 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138745258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Mechanistic Link Between Obesity and Heart Failure 探索肥胖与心力衰竭之间的机制联系

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-12-15 DOI: 10.1007/s11892-023-01526-y

Bige Ozkan, Chiadi E. Ndumele

{"title":"Exploring the Mechanistic Link Between Obesity and Heart Failure","authors":"Bige Ozkan, Chiadi E. Ndumele","doi":"10.1007/s11892-023-01526-y","DOIUrl":"https://doi.org/10.1007/s11892-023-01526-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Abstract</h3><h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Among subtypes of cardiovascular disease, obesity has a potent and unique association with heart failure (HF) that is unexplained by traditional cardiovascular risk mediators. The concomitant rise in the prevalence of obesity and HF necessitates better understanding of their relationship to develop effective prevention and treatment strategies. The purpose of this review is to provide mechanistic insight regarding the link between obesity and HF by elucidating the direct and indirect pathways linking the two conditions.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Several direct pathophysiologic mechanisms contribute to HF risk in individuals with excess weight, including hemodynamic alterations, neurohormonal activation, hormonal effects of dysfunctional adipose tissue, ectopic fat deposition with resulting lipotoxicity and microvascular dysfunction. Obesity further predisposes to HF indirectly through causal associations with hypertension, dyslipidemia, and most importantly, diabetes via insulin resistance. Low levels of physical activity and fitness further influence HF risk in the context of obesity. These various processes lead to myocardial injury and cardiac remodeling that are reflected by abnormalities in cardiac biomarkers and cardiac function on myocardial imaging.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Understanding and addressing obesity-associated HF is a pressing clinical and public health challenge which can be informed by a deeper understanding of the complex pathways linking these two conditions together.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and Severity of Menopausal Symptoms: a Contemporary Review. 肥胖与更年期症状严重程度:一项当代综述

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-12-01 Epub Date: 2023-11-24 DOI: 10.1007/s11892-023-01528-w

Vivian Cao, Alisha Clark, Brooke Aggarwal

引用次数: 0

Impact of the Neighborhood Food Environment on Dietary Intake and Obesity: a Review of the Recent Literature. 邻里食物环境对饮食摄入和肥胖的影响:近期文献综述。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-12-01 Epub Date: 2023-11-27 DOI: 10.1007/s11892-023-01529-9

Candice A Myers

引用次数: 0

Sexual Function and Satisfaction in the Context of Obesity. 肥胖背景下的性功能和满意度。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-11-01 Epub Date: 2023-08-26 DOI: 10.1007/s11892-023-01523-1

Sean M McNabney, Nana Gletsu-Miller, David L Rowland

{"title":"Sexual Function and Satisfaction in the Context of Obesity.","authors":"Sean M McNabney, Nana Gletsu-Miller, David L Rowland","doi":"10.1007/s11892-023-01523-1","DOIUrl":"10.1007/s11892-023-01523-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sexual dysfunction is commonly associated with overweight/obesity, but the underlying physiological and psychosocial mechanisms are not fully understood. This review contextualizes the obesity-sexual (dys)function relationship, describes recent insights from the medical and social science literature, and suggests opportunities for continued research.</p><p><strong>Recent findings: </strong>Although sexual dysfunction has been historically evaluated as a consequence/outcome of obesity, it is increasingly considered as a harbinger of future metabolic comorbidities, including type 2 diabetes and cardiovascular disease. Body image dissatisfaction is a consistent predictor for lower sexual satisfaction across BMI categories, likely mediated by cognitive distraction during partnered sex. To fully capture the relationship between obesity and sexual dysfunction, multidisciplinary research approaches are warranted. While clinically significant weight loss tends to improve sexual functioning for women and men, higher body image satisfaction may independently promote sexual function and satisfaction without concomitant weight loss.</p>","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"315-327"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10072950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarcopenic Obesity and Cardiometabolic Health and Mortality in Older Adults: a Growing Health Concern in an Ageing Population. 老年人肌肉减少性肥胖与心脏代谢健康和死亡率:老龄化人口中日益增长的健康问题。

IF 4.2 2区医学

Current Diabetes Reports Pub Date : 2023-11-01 Epub Date: 2023-08-11 DOI: 10.1007/s11892-023-01522-2

Sasiwarang Goya Wannamethee, Janice L Atkins

引用次数: 0